Ironwood Pharmaceuticals, Inc. (IRWD) Monday said it expects revenue for the fiscal 2023 to be in the range of $435 million - $450 million, same as the previous outlook.
On average, 3 analysts polled by Thomson-Reuters expect the company to report revenue of $444.01 million for the year.
For the year 2024, the company sees revenue between $435 million and $455 million.
Ironwood expects adjusted earnings before interest, taxes, depreciation, and amortization or EBITDA for fiscal 2023 to be a loss of $900 million, while seeing a gain of $150 million for fiscal 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.